As shown in panels a–i of Figure 5, to explore the differences in the association between radiomics features and TP53 mutation status across different tumor types, we conducted feature differential analyses separately in patients with cervical cancer, ovarian cancer, and endometrial cancer. This evidence concerns the gene TP53 and ovarian cancer.